WCLC 2025
September 6, 2025 - September 9, 2025
Vienna, Austria
Amid a packed fall season of international congresses, Nordic Bioscience is excited to take part in the World Conference on Lung Cancer (WCLC) 2025, hosted by IASLC and held September 6–10 in Vienna, Austria.
This premier event gathers global experts to accelerate progress in lung cancer research, diagnosis, and treatment. Nordic Bioscience will contribute to the dialogue with a focus on tumor fibrosis biomarkers, which play a key role in understanding the tumor microenvironment and predicting therapeutic outcomes.
Our team will spotlight nordicPRO-C3™, a blood-based biomarker that quantifies type III collagen turnover—a signature of cancer-associated fibroblast (CAF) activity and fibrotic remodeling in solid tumors. Backed by a Letter of Support from the FDA, nordicPRO-C3™ is being explored as a non-invasive tool to track tumor fibrosis and treatment response in lung cancer and beyond.
We look forward to joining researchers and clinicians at WCLC to explore how fibrosis biomarkers can support the future of precision oncology.